Alligator Bioscience AB (ATORX) AI Stock Analysis

Alligator Bioscience is a biotechnology company historically focused on tumor-directed immuno-oncology. Following a strategic refocus, it is prioritizing its economic interest in HLX22, an anti-HER2 monoclonal antibody developed by Shanghai Henlius,...

Alligator Bioscience has agreed to sell all global rights and assets related to its CD40 agonist antibody mitazalimab to Biossil Inc., including patents, clinical and regulatory data, manufacturing materials, drug inventory, and all future developmen...

Alligator Bioscience AB has increased its number of shares and votes following a rights issue of units approved by the board in July 2026 and confirmed by an extraordinary general meeting in August 2026. As of 30 October 2026, the company’s tot...

Alligator Bioscience AB plans to seek shareholder approval at an Extraordinary General Meeting on 27 November 2026 for a 1-for-1,000 reverse split of its ordinary shares, consolidating the total number from about 3.57 billion to roughly 3.57 million...

Alligator Bioscience AB has called an extraordinary general meeting for 27 November 2026 in Lund, Sweden, inviting shareholders to vote on a series of corporate actions. The meeting will address share capital restructuring measures, board composition...

Alligator Bioscience has undertaken a strategic refocus in the third quarter of 2026, discontinuing independent development of its lead asset mitazalimab and concentrating on its financial interest in HLX22, which is advancing through global Phase 3...

Alligator Bioscience will publish its interim report for the July–September 2026 period, focused on its HER2-targeting activities, on 22 October 2026 at 8:00 a.m. CEST. The company will the same day host an English-language webinar and conferen...

Alligator Bioscience has appointed its current Chief Financial Officer, Johan Giléus, as Chief Executive Officer effective 1 January 2027, succeeding Søren Bregenholt, who will remain in the role until the end of 2026 to ensure a smooth han...

Alligator Bioscience has issued 187,795,097 warrants to Fenja Capital as part of a renegotiated loan arrangement linked to its recently completed rights issue. The new 2026/2031 warrants, replacing an earlier 2025/2030 series, correspond to about 5 p...

Alligator Bioscience has reported the final outcome of its rights issue of units, in which only about 17.1 percent of the maximum 3.14 billion units were subscribed by investors, with the remainder largely covered by guarantee commitments. Each unit...

Alligator Bioscience AB has reported the preliminary outcome of its rights issue of units, launched in July 2026, with subscriptions totaling about 17.1 percent through exercise of unit rights and 16.7 percent without rights. This level of demand mea...

Alligator Bioscience has published a prospectus for a rights issue of up to 3,140,534,240 units, each comprising two shares and two series of warrants, at a subscription price of SEK 0.04 per unit. The offer, running from 4 to 18 September 2026, coul...

Alligator Bioscience’s extraordinary general meeting approved multiple changes to its capital structure, including amendments to the Articles of Association and significant reductions of share capital to cover losses and reallocate funds to unr...

Alligator Bioscience reported a weak second quarter with no significant operational events, continuing to post operating losses and declining cash, while progressing investigator-led studies and data presentations for mitazalimab and highlighting enc...